Kurzfassung

A randomized,observer blin,multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz)in comparison to Metvix in the treatment of non-aggressive basal cell carcinoma ( BCC) with photodynamic therapy (PDT)